Seven cases of agranulocytosis and two ofliver damage that were probably due to amodiaquine treatment were studied. In five cases agranulocytosis was combined with liver damage, and in one case of primary liver damage moderate neutropenia was present. Three patients died. High total doses or prolonged duration of treatment, or both, appear to favour the occurrence of these reactions.
Introduction 8 x 106/1,72 x 106/1, and 73 x 106/1, respectively. Neutrophils werenot detected Amodiaquine (Camoquin, Parke-Davis) is a 4-aminoquinoline derivative used in the prophylaxis and treatment of malaria, and also for the treatment of rheumatoid diseases. Agranulocytosis'-'°and liver damage" 12 have repeatedly been reported as adverse reactions to amodiaquine. For reasons unknown both reactions seem to occur together more often than expected by chance.
In 1982 and 1983 we observed two patients with amodiaquine induced agranulocytosis and detected a drug dependent granulocytotoxic antibody in the serum of one of these patients." Between February and July 1985 five further patients with suspected amodiaquine induced agranulocytosis were transferred to our The local clustering of five cases of amodiaquine induced agranulocytosis .within six months raises questions about the incidence and epidemiology of thds drugreaction. Ifwe assume that our medical centre has a maximum referral area with one million inhabitants about 30 000-35 000 of these subjects are expected to require malaria prophylaxis during a period of six moniths (Swiss 
